TANVEX BIOPHARMA, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 39 TWD | -1.39% |
|
-8.88% | -40.09% |
| Sales 2022 | 22.4 721.1 | Sales 2023 | 61.41 1.98K | Capitalization | 8.71B 280B |
|---|---|---|---|---|---|
| Net income 2022 | -1.64B -52.82B | Net income 2023 | -2.14B -68.78B | EV / Sales 2022 | 599,427,887 x |
| Net Debt 2022 | 1.05B 33.89B | Net Debt 2023 | 1.35B 43.48B | EV / Sales 2023 | 163,906,538 x |
| P/E ratio 2022 |
-7.54
x | P/E ratio 2023 |
-3.93
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.81% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -1.39% | ||
| 1 week | -8.88% | ||
| Current month | -16.84% | ||
| 1 month | -14.00% | ||
| 3 months | -36.89% | ||
| 6 months | -43.64% | ||
| Current year | -40.09% |
1 week
35.05
40.60
1 month
35.0548.30
Current year
35.0566.50
1 year
35.0582.30
3 years
35.05245.22
5 years
35.05299.78
10 years
35.051 034.21
| Managers | Title | Age | Since |
|---|---|---|---|
Kuan Hao Lin
DFI | Director of Finance/CFO | - | 22-02-17 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
ALLEN Chao
FOU | Founder | 78 | 13-05-07 |
Ta Meng Tseng
BRD | Director/Board Member | 66 | 13-10-05 |
Chih Chuan Chen
BRD | Director/Board Member | - | 13-10-05 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 7 M€ | +0.11% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-22 | 39 | -1.39% | 197,160 |
| 24-05-21 | 39.55 | +7.04% | 463,338 |
| 24-05-20 | 36.95 | -4.27% | 907,185 |
| 24-05-17 | 38.6 | -9.92% | 875,398 |
| 24-05-16 | 42.85 | +0.12% | 298,000 |
End-of-day quote Taiwan S.E., May 21, 2024
More quotes
Tanvex BioPharma, Inc. is a Cayman Islands-based biopharmaceutical company focused on the biosimilar market. The company has expertise in areas, including strain and cell-line development in both microbial and mammalian systems, cell culture, protein purification, process scale-up, drug substance and product manufacturing, and others. The Companyâs product pipeline includes Neupogen (TX-01), Herceptin (TX-05), Neulasta (TX-04), Avastin (TX-16), Perjeta (TX-52), and others. The Company offers a vertically integrated manufacturing platform for biopharmaceuticals. The Company is developing and delivering biologic and biosimilar drugs to people.
Calendar
2024-06-18
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -40.09% | 198M | |
| +9.99% | 115B | |
| +12.01% | 106B | |
| -3.07% | 24.69B | |
| -0.90% | 21.97B | |
| -4.92% | 19.27B | |
| -6.90% | 17.56B | |
| -39.36% | 17.32B | |
| +5.82% | 14.03B | |
| +33.05% | 12.13B |
- Stock Market
- Equities
- 6541 Stock
